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Irritable bowel syndrome (IBS) is a functional syndrome characterized by chronic abdominal pain accompanied by
altered bowel habits. Although generally considered a functional disorder, there is now substantial evidence that IBS
is associated with a poor quality of life and significant negative impact on work and social domains. Neuroimaging
studies documented changes in the prefrontal cortex, ventro-lateral and posterior parietal cortex and thalami, and
implicate alteration of brain circuits involved in attention, emotion and pain modulation. Emerging data reveals the
interaction between psychiatric disorders including generalized anxiety disorder, panic disorder, major depressive
disorder, bipolar disorder, and schizophrenia and IBS, which suggests that this association should not be ignored when
developing strategies for screening and treatment. Psychological, social and genetic factors appear to be important in
the development of IBS symptomatology through several mechanisms: alteration of HPA axis modulation, enhanced
perception of visceral stimuli or psychological vulnerability. Elucidating the molecular mechanisms of IBS with or
without psychiatric comorbidities is crucial for elucidating the pathophysiology and for the identification of new
therapeutical targets in IBS.
Keywords: Irritable bowel syndrome, Psychiatric disorders, Comorbidities, Brain-gut axis, Psychosocial factorsReview
Introduction
Irritable bowel syndrome (IBS) is a functional syndrome
characterized by chronic abdominal pain accompanied
by altered bowel habits [1,2]. IBS is a painful condition
associated with significant psychological distress and
psychiatric comorbidities, like higher levels of anxiety
or depression and suicidal ideation, with negative impact
on quality of life [2,3]. Its consequences are measured
in direct cost (medical treatment and procedures) and
indirect cost (reduced productivity) [4].
The Rome committee published in 1992 the first clinical
diagnostic criteria of IBS that could be also used in
research. The latest version, Roma III diagnostic criteria,
are the current golden standard for diagnosing IBS
patients. According to these criteria, IBS is defined as
recurrent abdominal pain or discomfort at least 3 days/* Correspondence: ddumitrascu@umfcluj.ro
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article, unless otherwise stated.month in the last 3 months associated with two or more
of the following: a) improvement with defecation, b) onset
associated with a change in the frequency of stool, c) onset
associated with a change in form (appearance) of stool.
IBS can be subtyped into categories based on the main
bowel habit: IBS with constipation (IBS-C), IBS with
diarrhea (IBS-D), mixed IBS (IBS-M), and unsubtyped
IBS (IBS-U) [5].
Depending on diagnostic criteria used (Manning, Rome I,
Rome II, Rome III), IBS is estimated to affect approximately
11% of the global population. A recent meta-analysis
shows the lowest occurrence in South Asia (7%) and
the highest in South America (21%) [6]. IBS is reported
more frequently by women than men in Western countries,
female–male odd ratio being 2:1 and seems to be more
common in the ages between 20 and 40. Based on different
symptoms observed, the researchers speculated that sex
hormones may alter the regulatory mechanisms of the
brain-gut-microbiota axis involved in the pathophysiology
of IBS [7].Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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has been attributed to dysregulation of the brain-gut
axis, HPA axis, altered gastrointestinal motility, visceral
hypersensitivity, infectious factors, enhanced immuno-
logical reactivity, genetic susceptibility and psychosocial
factors. Communication between central nervous system
and enteric nervous system implies a bidirectional connec-
tion system: the brain influences the function of the enteric
nervous system, and the gut influences the brain via vagal
and sympathetic afferents. The symptoms may be caused
by dysfunctions either primarily in the central nervous
system, or in the gut, or by a combination of both [8-11].
Stress often worsens the symptoms of patients with
IBS. Hypothalamic-pituitary-adrenal axis (HPA axis) is an
important component of regulatory mechanisms govern-
ing behavioural, neuroendocrine and autonomic responses
to stress. The hypothalamic-pituitary-adrenal (HPA) axis
and the sympathetic nervous system (SNS) are the two
major branches of this central stress response system.
Hyperactivation of this pathway may be involved in IBS
pathophysiology. For example, a hyperreactive responce of
the brain and gut to corticotropin-releasing hormone
(CRH) and alterations in adrenocorticotropin hormone
(ACTH) and cortisol, and catecholamine levels have
been reported in IBS patients [12-14]. Indeed, peripheral
administration of CRH improved colonic function and
visceral perception in response to gut stimulation in
IBS patients [13]. In addition, previous studies showed
that the IBS is associated with significantly lower vagal
tone and increased sympathetic activity [14]. Therefore
it has been proposed that the interaction between different
factors like brain-gut axis, HPA axis and inflammatory
response can exacerbate IBS symptoms and therefore
may play an important role in IBS etiology [9].
Gastrointestinal symptoms have been recognized to
occur in relation to fear, anxiety and stress. The gut
motility has been found to be reactive to changes in the
emotional state. Also, stress has been showed to affect
both motility and visceral hypersensitivity. Over the past
several years, a great deal of research has evaluated the
relationship between IBS and psychiatric disorders. Rates
of co-morbidity with psychiatric disorders range from 54
to 94% in treatment-seeking patient with IBS [15-17].
Psychiatric disorders and IBS appear to have bidirec-
tional co-morbidities. The frequency and severity of the
symptomatology of IBS in patients with anxiety and
mood disorders have been well documented. Evolution
of IBS symptoms seems to be influenced by affective
factors and psychosocial stressors [2,18]. Those factors
may contribute to predisposition, precipitation and
maintenance of IBS symptoms, and they also influence
the clinical outcome [3,19]. Psychiatric interventions
(pharmacologic or psychotherapy) have proved effect-
iveness in the improvement of IBS patient functioning.In this review, we emphasize the relationship between
IBS and psychiatric disorders.
Brain imaging studies
Patients with IBS also exhibit differences in brain morph-
ology, when compared with healthy volunteers. IBS patients
showed association of disease onset with thicker right
posterior insula, but the association with psychological
symptoms was not proved [20]. The results of another
study support the hypothesis that IBS patients with
chronic pain exhibit long-term microstructural changes
within the brain, particularly in cortical regions associated
with integration of sensorial information and corticothala-
mic modulation [21]. For example, patients with IBS also
showed increased hypothalamic gray matter [22,23] that
may be related to pain-related overstimulation of the
hypothalamic-pituitary-adrenal axis. Likewise, IBS was
associated with decreased gray matter density (GMD)
in different regions of the brain (medial prefrontal cortex,
ventro-lateral prefrontal and posterior parietal cortex,
ventral striatum, and thalami) [24]. Changes in the density
of gray matter among regions involved in cognitive
functions are specifically observed in patients with IBS,
albeit different levels of anxiety and depression can
explain changes in other areas of the brain. The findings
of another study on a sample of female IBS patients with
moderate symptom severity suggest that morphometric
alterations occur primarily in brain networks involved in
attention and emotion modulation, as well as in pain
modulatory networks, and in systems processing intero-
ceptive information [22].
Changes in gray matter volume and cortical thickness
(CT) have been demonstrated in subjects with IBS, espe-
cially in female IBS [16,25]. Also, compared with healthy
subjects, in IBS patients, the right part of cingulate gyrus
and thalamus are critical for information flow. Brain areas
involved in pain modulation were identified as network
hubs in IBS [23,26].
About 15 years ago, functional brain imaging was in-
troduced as a novel method to examine the interactions
between gut and brain. The technique has provided
the opportunity to assess the neurobiological substrates
involved in human behavior and visceral homeostasis.
Recent studies in neuroscience have shown that the brain
functions involved in emotion are modulated by visceral
pain. The researchers identified two important neural
networks with abnormal functioning: the lateral prefrontal
regions of the descending pain inhibition network, and
the emotion-arousal networks. Furthermore functional
imaging studies may provide relevant information about
cognitive mechanisms, which may be involved in neuro-
biological abnormalities of IBS [27,28].
Functional MRI (fMRI) studies point to dysfunction of
emotion and attention processing of pain in IBS. Patients
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placebo analgesia by decreased brain activity related to
cerebral mechanisms involved in memory and semantic
processing [29]. Since then, an increasing number of
imaging studies assessed the brain activity in regions
involved in processing the visceral homeostatic afferent
input and have shown abnormal activity in different regions
of the brain (anterior/mid cingulate cortex primary and
secondary somatosensory cortex, insular cortex, thalamic
and prefrontal cortex).
The affective component of physical pain is processed
cortically by the dorsal anterior cingulate cortex and the
anterior insula. Both regions have some of the highest
numbers of mu-opioid receptors in the central nervous
system [30]. The perception of pain is modulated by
several factors like affective and sensory aspects of the
painful stimulus, coping strategies and personality features
[31,32]. Catastrophic thinking increases the frequency of
maladaptive thoughts about pain and neuroticism is corre-
lated with increased sensitivity to negative cues.
A quantitative meta-analysis of available data revealed
that patients with IBS appears to show greater activation
of amygdale and perigenual anterior cingulate gyrus
nodes, but similar activation of regions involved in the
processing of visceral afferent information, as compared
with healthy controls [32]. Further, patients with IBS have
increased activity in the insula and decreased activation of
the dorsolateral prefrontal cortex in response to visceral
stimulation [33,34].
One recent study investigated if the patients have im-
pairments in cognitive flexibility due to dysfunction in
the dorsolateral prefrontal cortex and insula, and altered
connectivity between brain regions. Event-related fMRI
of the brain was performed to evaluate cognitive flexibil-
ity and was assessed by the Wisconsin Card Sorting Test
(WCST). The subjects with IBS presented significantly
more perseverative errors, and set-maintenance difficulties
than controls. The results showed significantly increased
activity of the left posterior insula at error feedback during
set-shifting, and significantly decreased activity of the right
dorsolateral prefrontal cortex, and right hippocampus in
subjects with IBS [34].
Some other studies showed that in IBS, rectal distention
determine anterior cingulate cortex (ACC) activation that
correlates with anxiety, maladaptive coping, stressful events
and a history of abuse. IBS diagnosis and abuse history
appear to have synergistic effects causing even greater
activation of the perigenual pACC. These studies support
clinical observations regarding the connections between
psychological distress, IBS, and increased pain [35].
Panic disorder and IBS
Panic disorder (PD) is a frequent psychiatric disorder,
with a lifetime prevalence between 1.5% and 3.5%.Agoraphobia is present in 20,2% of patient affected by
PD [36,37].
High comorbidity between IBS and PD has been iden-
tified in the literature [3,17,38]. The prevalence of IBS
symptoms characteristics in patients with PD varies be-
tween 25 to 44%, several symptoms being characteristic of
the two disorders (nausea, diarrhea, abdominal discom-
fort) [39-42].
Recent studies tried to clarify the nature of the rela-
tionship between PD and IBS. One explanatory model is
represented by the functional relationship between the
central nervous system (CNS) and enteric nervous system
(ENS). Much of the results of recent research suggest
that the dysregulation of hypothalamic-pituitary-adrenal
axis (disruption of the normal inhibitory feed-back) may
represent a common pathway that may lead to stress
vulnerability [41,43,44]. Patients with IBS and anxiety
disorders present abnormally elevated basal cortisol levels
and altered immune function (increased cytokines levels)
[45-47].
There is evidence that the presence of avoidant behavior
because of fear of IBS symptoms may be linked to a more
severe form of agoraphobia, and the latter may also be
associated with depression. The results of a recent study
imply that presence of IBS may be related to anticipatory
anxiety and agoraphobia in patients with PD [47,48].
Generalised anxiety disorder and IBS
Gastrointestinal-specific anxiety seems to perpetuate IBS
symptoms through disruption of autonomic and pain fa-
cilitation, as well as cognitive mechanisms. Anticipatory
worries and avoidance behavior are the main reason of
affected functioning [49,50]. One study examined the
relationship between IBS and GAD among IBS patients
and healthy subjects and 32% of subjects with IBS pre-
sented GAD symptoms as compared with other psycho-
logical manifestations [50]. According to this study, visceral
sensitivity score (VSI) is the single powerful predictor of
the severity of gastrointestinal-specific anxiety (GSA). An-
other study examined the prevalence, comorbidity and risks
correlates of IBS in a general population and confirmed that
there is a strong association between IBS and GAD, i.e.,
patients with comorbid IBS-GAD had more functional
impairment and had more depressive symptoms [51].
Both diseases may benefit from treatment with antide-
pressants (selective serotonin reuptake inhibitors-SSRIs).
Serotonin stimulates gastro-intestinal motility and visceral
perception at CNS level by activating the serotonin recep-
tor. SSRIs used for anxiety disorders and/or depression
can improve the outcome of patients with IBS and associ-
ated psychiatric disorders, in special with constipation-
predominant IBS form. However, is not entirely clear if
the mechanism underlying IBS are linked to the drugs
effects on mood [52].
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efficiency of duloxetine treatment in comorbid IBS and
GAD. Patients reported significant reductions in IBS
symptoms, as well as improvement in GAD [53].
Post traumatic stress disorder and IBS
A number of studies have consistently reported a rela-
tionship between history of various type of abuse and
IBS. It is not clarified yet what is the connection between
posttraumatic stress disorder (PTSD) and IBS. Much of
the research had been focused on the role of sexual abuse
as a risk factor to acquire IBS with most studies reporting
an increased IBS risk [54,55].
Another study reported that 36% of patients with IBS
have met lifetime diagnostic criteria of PTSD [56].
Other authors reported a substantially increased risk for
IBS among female veterans diagnosed with PTSD or for
military after deployment to war [57,58]. Indeed, one case
study demonstrated that treating PTSD symptoms first
may contribute to an improvement in IBS symptoms [59].
Major depressive disorder and IBS
One of the most diagnosed psychiatric disturbances in
IBS patients is depression. There are many studies that
evaluated the prevalence of anxiety and depression among
patients with IBS seeking care in gastroenterology units
but few studies have been done on IBS in psychiatric
patients. An increased prevalence (27–47, 3%) of IBS in
patients with major depression (onset or recurrent episode)
was reported by several studies [60,61]. More recently, a
cross-sectional study investigated the prevalence of IBS
symptoms in patients diagnosed with major depressive
disorder (MDD) [62]. The results demonstrated a higher
prevalence of IBS symptoms in patients with depression
compared with healthy subjects but patients with MDD in
remission did not differ from healthy controls in reporting
gastrointestinal symptoms.
Females with IBS have abnormal increased trypto-
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Serotonin transporterupregulation by proinflammatory cytokines. The rapid
degradation of tryptophan depletes tryptophan and sero-
tonin and produces toxic metabolites. This mechanisms
could represent a possible biological basis for the high
co-morbidity between IBS and depressive and anxiety
disorders [63,64].
Bipolar disorders and IBS
There are very few studies assessing the association
between bipolar disorder and IBS. One community study
found a lack of association between bipolar disorder and
IBS [65]. Another case study reported no significant rela-
tionship between mood and IBS symptom severity [66].
Schizophrenia and IBS
Schizophrenia is a chronic disease associated with a high-
risk of developing comorbid somatic illnesses. Somatic
co-morbidities represent a major issue in patients with
schizophrenia. The prevalence of IBS in schizophrenia
patients was reported by Gupta and colleagues, to be
17% [67]. Another study reported a prevalence of 19%
[68]. One of the main findings of this study was that
patients with schizophrenia rarely complain about IBS
symptoms, unless specifically asked. In patients with
schizophrenia there may be significant barriers in obtain-
ing adequate health care when comorbid disorders occur.
These obstacles may be the result of patient psychotic
symptomatology, stigma, and financial problems. It should
be remembered that, under these circumstances, the
actual prevalence of IBS symptoms may be higher, as
these results are dependent upon individual reporting
of symptoms.
Alcohol abuse/dependence and IBS
The findings relating alcohol abuse and IBS are contra-
dictory. In population-based studies, alcohol abuse was
not found to be associated with IBS. Moreover, the
majority of patients with IBS tried to avoid certain food
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concluded that IBS is underdiagnosed in patients with
alcohol abuse and alcohol dependence [61]. The findings
of a recent study investigating the role of alcohol ingestion
on gastrointestinal symptoms provided indication that
it is the pattern of alcohol consumption may influence
symptomatology in IBS patients [70].Genes involved in ibs and psychiatric comorbidities
The pathogenesis of IBS associated with psychiatric co-
morbidities appears to have multifactorial aspects. Several
factors appear to play a role in this process, such as
psychological factors, genetic factors, chronic intestinal
inflammation, and/or altered signaling in CNS and gut
neuroendocrine system (NES) (Table 1). The IBS is not
a “single gene” disease, many factors involved in IBS (e.g.
individual vulnerability, psychosocial stressors) can be
modulated by targeting these diseases at molecular level
(interaction between genes and/or signaling pathway
modulation in response to environment).
Neurotrophins like NGF (nerve growth factor) or Brain-
derived neurotrophic factor (BDNF) are involved, not
only in somatic and visceral hypersensitivity, but also
in neuronal survival, maturation and migration in the
peripheral and central nervous system (CNS). Previous
studies have reported a massive release of NGF in the
peripheral circulation together with increased mRNA level
in hypothalamus to integrate behavioral and neuroendo-
crine response following a psychosocial stress. Systemic
administration of an anti-NGF antibody can prevent co-
lonic hypersensibility and can be considered as a potential
new therapeutic target [71,72].
BDNF promote neural plasticity and plays an important
role in the modulation of stress response and pathophysi-
ology of mood disorders. Many studies were focused on
the genetic polymorphisms associated with IBS. Yu and
colleagues showed that the increased BDNF expression as
compared with healthy controls in gut biopsies is associ-
ated with IBS [73]. On the other hand, BDNF Val66Met
single nucleotide polymorphism (BDNF Val66Met SNP)
was associated with decreased BDNF secretion from neu-
rons and may lead to impairments in learning and altered
susceptibility to stress [74].
Polymorphisms that affect many systems like seroto-
nergic, adrenergic and opioidergic systems may also be
involved in IBS pathophysiology. Adrenergic and opioider-
gic systems are involved in the modulation of motor
and sensory function of gut and their polymorphism
has been correlated with differential response to pain
and with variation in alteration of gut motility [75-78].
Serotonin transporter gene (SERT) polymorphisms are
associated with higher risk of depression in IBS patients.
Thus individuals with a diminished function of serotonintransporters are more sensitive to gut signals in emotion-
regulating brain regions [79,80].
Conclusions
A number of psychiatric comorbidities affect the patients
with IBS. In particular, anxiety disorders and mood disor-
ders occur with a significant greater frequency, indicating
that the assessment or treatment of these comorbid condi-
tions may influence the outcome of IBS. Although symp-
toms may improve with pharmacologic treatment, the
residual manifestations of IBS may still impact the social
and occupational functioning. Elucidating the molecular
mechanisms of IBS with or without psychiatric comorbidi-
ties is crucial for elucidating the pathophysiology and for
the identification of new therapheutical targets in IBS. A
lot of data suggest the benefit of adjunctive psychological
and genetical interventions but further investigation of
such interventions is required.
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